Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWE | ISIN: US03969K1088 | Ticker-Symbol:
NASDAQ
06.10.25 | 17:04
20,310 US-Dollar
+2,01 % +0,400
1-Jahres-Chart
ARCUTIS BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ARCUTIS BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ARCUTIS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:06Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children1
14:06Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5169ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere...
► Artikel lesen
FrArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)84WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
► Artikel lesen
29.09.Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 20255
29.09.Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% In 20255
17.09.Arcutis Biotherapeutics, Inc.: Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress7
ARCUTIS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
16.09.Arcutis Biotherapeutics, Inc.: Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award9
10.09.Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung1
05.09.Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)186WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
► Artikel lesen
03.09.Arcutis seeks FDA approval for psoriasis cream for young children3
03.09.Arcutis Biotherapeutics, Inc.: Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5217If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to...
► Artikel lesen
03.09.Arcutis präsentiert Wachstumsstrategie und Pipeline-Updates auf Citi-Konferenz2
08.08.Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)298WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
► Artikel lesen
07.08.Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 20267
06.08.Arcutis Biotherapeutics GAAP EPS of -$0.13 beats by $0.02, revenue of $81.5M beats by $7.83M7
21.07.Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth4
21.07.Guggenheim bestätigt Kaufempfehlung für Arcutis Biotherapeutics nach starkem Verschreibungswachstum11
17.07.Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%3
03.07.Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)386WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
► Artikel lesen
03.07.Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating4
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4